UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/18.09.24 | Real-time BOERSE MUENCHEN 01:41:34 2024-05-24 pm EDT | ||
| 0.41 EUR | +20.59% |
|
| Current month | +183.33% | ||
| 1 month | +61.90% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-24 | 0.41 | +20.59% |
| 24-05-23 | 0.34 | +25.93% |
| 24-05-22 | 0.27 | +22.73% |
| 24-05-21 | 0.22 | -26.67% |
| 24-05-20 | 0.3 | +7.14% |
Real-time BOERSE MUENCHEN
Last update May 24, 2024 at 01:41 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD0BHZ |
| ISIN | DE000HD0BHZ7 |
| Date issued | 2023-10-31 |
| Strike | 550 $ |
| Maturity | 2024-09-18 (117 Days) |
| Parity | 10 : 1 |
| Emission price | 0.68 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.82 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.07 € |
| Spread % | 16.28% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
450.8
USD
Average target price
462.8
USD
Spread / Average Target
+2.66%
- Stock Market
- Warrants
- Warrant
